KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Capital Expenditures (2016 - 2025)

Evolent Health (EVH) has 11 years of Capital Expenditures data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 26.17% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $34.1 million, up 36.94%, while the annual FY2025 figure was $34.1 million, 36.94% up from the prior year.
  • Capital Expenditures reached $7.8 million in Q4 2025 per EVH's latest filing, down from $9.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $10.7 million in Q4 2022 and bottomed at $5.3 million in Q1 2024.
  • Average Capital Expenditures over 5 years is $7.8 million, with a median of $7.8 million recorded in 2025.
  • Peak YoY movement for Capital Expenditures: tumbled 43.67% in 2023, then skyrocketed 60.74% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $5.9 million in 2021, then skyrocketed by 80.83% to $10.7 million in 2022, then crashed by 43.67% to $6.1 million in 2023, then grew by 1.64% to $6.2 million in 2024, then rose by 26.17% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $7.8 million in Q4 2025, $9.0 million in Q3 2025, and $8.8 million in Q2 2025.